WallStreetZenWallStreetZen

NASDAQ: BIIB
Biogen Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for BIIB

Based on 20 analysts offering 12 month price targets for Biogen Inc.
Min Forecast
$213.00+11.8%
Avg Forecast
$288.15+51.24%
Max Forecast
$373.00+95.78%

Should I buy or sell BIIB stock?

Based on 20 analysts offering ratings for Biogen Inc.
Buy
Strong Buy
7 analysts 35%
Buy
7 analysts 35%
Hold
6 analysts 30%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BIIB stock forecasts and price targets.

BIIB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-17
lockedlocked$00.00+00.00%2024-04-17
lockedlocked$00.00+00.00%2024-04-12
lockedlocked$00.00+00.00%2024-04-11
lockedlocked$00.00+00.00%2024-04-04
Truist Securities
Bottom 4%
4
Strong BuyReiterates$340.00+78.46%2024-03-25
RBC Capital
Top 4%
97
BuyReiterates$364.00+91.06%2024-03-05
Mizuho
Bottom 15%
15
Strong BuyMaintains$277.00+45.39%2024-02-22
Cantor Fitzgerald
Top 32%
69
Strong BuyReiterates$311.00+63.24%2024-02-20
Canaccord Genuity
Bottom 6%
6
Strong BuyMaintains$305.00+60.09%2024-02-20

1 of 2

Forecast return on equity

Is BIIB forecast to generate an efficient return?
Company
N/A
Industry
15.54%
Market
35.66%

Forecast return on assets

Is BIIB forecast to generate an efficient return on assets?
Company
N/A
Industry
5.84%

BIIB revenue forecast

What is BIIB's revenue in the next 3 years based on estimates from 27 analysts?
Avg 1 year Forecast
$9.5B-3.69%
Avg 2 year Forecast
$9.6B-2.74%
Avg 3 year Forecast
$10.0B+1.4%
BIIB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BIIB earnings growth forecast

How is BIIB forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
31.51%
Industry
72.35%
Market
21.73%
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

BIIB revenue growth forecast

How is BIIB forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
0.47%
Industry
8.95%
Market
10.23%
BIIB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BIIB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BIIB vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
BIIB$190.52$288.15+51.24%Buy
OGN$17.86$20.00+11.98%Buy
GRFS$6.54$10.50+60.55%Hold
AMRN$0.87$1.00+14.68%Hold
SCLX$0.90$12.00+1,233.33%Buy
View Top General Drug Manufacturer Stocks

Biogen Stock Forecast FAQ

Is Biogen Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 20 Wall Street analysts covering (NASDAQ: BIIB) stock is to Buy BIIB stock.

Out of 20 analysts, 7 (35%) are recommending BIIB as a Strong Buy, 7 (35%) are recommending BIIB as a Buy, 6 (30%) are recommending BIIB as a Hold, 0 (0%) are recommending BIIB as a Sell, and 0 (0%) are recommending BIIB as a Strong Sell.

If you're new to stock investing, here's how to buy Biogen stock.

What is BIIB's revenue growth forecast for 2024-2026?

(NASDAQ: BIIB) Biogen's forecast annual revenue growth rate of 0.47% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Biogen's revenue in 2024 is $9,835,600,000.On average, 27 Wall Street analysts forecast BIIB's revenue for 2024 to be $1,376,947,893,072, with the lowest BIIB revenue forecast at $1,333,374,249,542, and the highest BIIB revenue forecast at $1,418,389,965,861. On average, 27 Wall Street analysts forecast BIIB's revenue for 2025 to be $1,390,494,065,838, with the lowest BIIB revenue forecast at $1,224,519,362,352, and the highest BIIB revenue forecast at $1,664,671,858,696.

In 2026, BIIB is forecast to generate $1,449,771,908,541 in revenue, with the lowest revenue forecast at $1,269,270,137,624 and the highest revenue forecast at $1,810,178,017,494.

What is BIIB's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: BIIB) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - General industry average of 5.84%.

What is BIIB's Price Target?

According to 20 Wall Street analysts that have issued a 1 year BIIB price target, the average BIIB price target is $288.15, with the highest BIIB stock price forecast at $373.00 and the lowest BIIB stock price forecast at $213.00.

On average, Wall Street analysts predict that Biogen's share price could reach $288.15 by Apr 17, 2025. The average Biogen stock price prediction forecasts a potential upside of 51.24% from the current BIIB share price of $190.52.

What is BIIB's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: BIIB) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.